Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche/Corange divesting Retavase to Centocor; biotech firm to co-promote ReoPro with Lilly.

Executive Summary

CENTOCOR TO PROMOTE RETAVASE, REOPRO WITH 200-PERSON SALES FORCE following the proposed acquisition of Retavase (reteplase, r-PA) from Roche/Boehringer Mannheim. Under the agreement announced Feb. 12, Centocor will pay $335 mil. in cash to acquire U.S. and Canadian rights to Boehringer Mannheim's Retavase and will offer "to employ, upon closing of the transaction, many U.S.-based sales and marketing personnel who currently commercialize the product," the Malvern, Pa.-based firm said.
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS031689

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel